

Market Review



INVESTING

August 24, 2020

EQUITY INDICES	LAST	CHANGE	%CHG	52 WK-HIGH	52 WK-LOW	YTD
DOW JONES INDUSTRIAL AVERAGE	28,308.46	378.13	1.35%	29568.57	18213.65	-0.81%
S&P 500	3,431.28	34.12	1.00%	3399.96	2191.86	6.21%
NASDAQ COMPOSITE	11,379.72	67.92	0.60%	11326.22	6631.42	26.83%
S&P/TSX COMPOSITE	16,626.64	108.79	0.66%	17970.51	11172.73	-2.56%
STOXX EUROPE 50	3,008.30	49.47	1.67%	3539.89	2260.11	-11.60%
FTSE 100	6,104.73	102.84	1.71%	7689.67	4898.79	-19.06%
DAX PERFORMANCE-INDEX TR	13,066.54	301.74	2.36%	13795.24	8255.65	-1.38%
CAC40	5,007.89	111.56	2.28%	6111.41	3632.06	-16.23%
Nikkei 225 Index	22,985.51	65.21	0.28%	24115.95	16358.19	-2.84%
HANG SENG INDEX	25,551.58	437.74	1.74%	29174.92	21139.26	-9.36%
Shanghai SE Composite Index	3,385.64	4.96	0.15%	3458.79	2646.80	11.00%

Market Review

Global stocks gain as COVID-19 treatment hopes boost risk appetite.

Global equity markets gained for a second straight session on Monday and the U.S. dollar fell as signs of progress on treatments for COVID-19 buoyed risk appetite. The U.S. Food and Drug Administration has approved the emergency use of convalescent blood plasma to treat hospitalized COVID-19 patients. The FDA's decision was hailed by President Trump, just one day after he accused it of impeding the rollout of treatments for political reasons. However, the World Health Organization was cautious about endorsing the plasma treatment, citing "low quality" evidence that it works. Also boosting sentiment was a report the White House is considering fast-tracking an experimental COVID-19 vaccine being developed by AstraZeneca Plc and Oxford University for use in the U.S. before the November 3rd election, but before completion of Phase 2 trials. AstraZeneca denied having discussed an emergency use authorization for its potential vaccine with the U.S. government. The moves come ahead of the four-day Republican National Convention, which kicks off tonight, where President Donald Trump will be nominated to lead his party for four more years. Meanwhile, talks between Democrats and Republicans over the next phase of fiscal aid for the coronavirus remain stalled. This week investor focus will be on remarks from Federal Reserve Chairman Jerome Powell at the virtual symposium in Jackson Hole on Thursday, where he will talk on the monetary policy framework review. Investors will be looking for clues to how aggressively the central bank will try to manage the long-term economic recovery from the coronavirus pandemic.

The S&P500 and the Nasdaq opened sharply higher, hitting record highs on Monday, led by strength in mega-cap FAANG stocks. However, the mega-cap trade was volatile, as stocks lost ground in the morning, briefly dipped into negative territory, before rebounding. The economically sensitive cyclical sectors, such as energy, materials, financials and industrials, outperformed on the S&P500. Meanwhile, the real estate and healthcare sectors underperformed. Canada's TSX Composite Index traded higher on Monday, led by sharp gains in the energy sector amid higher crude oil prices. Crude prices rose on supply concerns as companies shuttered in 1 million barrels a day of offshore crude oil production in the Gulf of Mexico, because of the threat from Hurricane Marco and Tropical Storm Laura. However, gains were capped by Friday's data that showed the number of oil rigs in operation in the U.S. increased for the first time since March. The heavily weighted financials sector advanced ahead bank earnings season which kicks off on Tuesday morning with Bank of Nova Scotia and Bank of Montreal. There were no major economic releases on the Canadian calendar for Monday. However, investors will be looking ahead to second quarter GDP data to be released on Friday. Bank of Canada Governor Tiff Macklem will also speak at the Jackson Hole Symposium on Thursday.

S&P/TSX: LEADERS	LAST	CHANGE	%CHG
NFI Group Inc	\$17.69	\$1.13	6.82%
Methanex Corp	\$29.73	\$1.81	6.48%
Sleep Country Canada Holdings Inc	\$21.63	\$1.25	6.13%
Air Canada	\$16.97	\$0.98	6.13%
Whitecap Resources Inc	\$2.64	\$0.14	5.60%

S&P/TSX: LAGGARDS	LAST	CHANGE	%CHG
Aurinia Pharmaceuticals Inc	\$18.48	-\$1.25	-6.34%
Real Matters Inc	\$28.38	-\$1.21	-4.09%
Enghouse Systems Ltd	\$73.70	-\$2.20	-2.90%
Ivanhoe Mines Ltd	\$4.96	-\$0.14	-2.75%
Seabridge Gold Inc	\$23.75	-\$0.67	-2.74%

S&P/TSX INDUSTRY	LAST	CHANGE	%CHG	YTD
ENERGY	83.32	3.43	4.29%	-42.92%
MATERIALS	339.2	-1.07	-0.31%	26.38%
UTILITIES	297.21	2.01	0.68%	2.92%
FINANCIALS	274.2	4.51	1.67%	-13.08%
INDUSTRIALS	301.85	1.41	0.47%	5.55%
HEALTH CARE	50.82	0.72	1.44%	-33.50%
CONS. DISCRETIONARY	194.71	1.85	0.96%	-3.16%
CONS. STAPLES	660.4	1.22	0.19%	6.66%
INFO TECH.	167.65	-1.23	-0.73%	42.16%
COMMUNICATION SVCS	165.46	0.75	0.46%	-7.67%
REAL ESTATE	279.57	0.78	0.28%	-19.30%

GOVERNMENT BONDS	2YR	5YR	10YR	30YR
CANADA (YLD%)	0.28%	0.39%	0.56%	1.07%
U.S. (YLD%)	0.16%	0.28%	0.66%	1.36%

COMMODITIES/ FX	LAST	CHANGE	%CHG	YTD
CRUDE OIL WTI	\$42.40	\$0.060	0.14%	-30.61%
NATURAL GAS	\$2.52	\$0.067	2.74%	14.89%
GOLD	\$1,923.00	-\$11.600	-0.60%	26.55%
COPPER	\$2.92	\$0.003	0.10%	4.38%
CAD / USD	\$0.7559	-\$0.0031	-0.41%	-1.83%
CAD / EUR	€0.6411	€0.0025	-0.39%	-6.63%
USD / EUR	€0.8482	€0.0002	0.02%	-4.88%
USD / JPY	¥105.97	¥0.19	0.18%	-2.43%

Source: Refinitiv



1) National Bank Financial is an indirect wholly owned subsidiary of National Bank of Canada.

2) National Bank of Canada is a public company listed on Canadian stock exchanges.

3) National Bank Financial may act as financial advisor, fiscal agent or underwriter for certain companies mentioned herein and may receive remuneration for its services.

4) National Bank Financial and/or its officers, directors, representatives or associates may have a position in the securities mentioned herein and may make purchases and/or sales of these securities from time to time in the open market or otherwise.

5) The information contained herein was obtained from sources which we believe to be reliable, however we cannot represent that it is accurate or complete.

6) This is not a recommendation for any security or investment sector as it may not be suitable for all types of investors. Please contact your investment advisor before purchase to discuss your investor profile and to further discuss these risk factors.